Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Complete if Known

Application Number 10/069,481

Filing Date February 27, 2002

First Named Inventor H. TAKAYAMA et al.

Group Art Unit

(use as many sheets as necessary)

of

Sheet

			 U.S. PATENT DOCUM	IENTS	
Examiner nitials*	Cite	U.S. Patent Docume Number Kind C	Name of Patentee or Applicant/Inventor	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,877,168 ~,	MIYAMOTO et al.	March 2, 1999	
oma	AB	5,824,811 \	KUBODERA et al.	Oct. 20, 1998	
2	AC	5,401,732	CALVERLEY et al.	March 28, 1995	
1	AD	5,378,695	CALVERLEY et al.	Jan. 3, 1993	
	AE	4,891,364	KUBODERA et al.	Jan. 2, 1990	
	AF	5,436,401	KATO et al.	July 25, 1995	
		7			
_/					
/					
	abla				
	- 1				

**Examiner Name** 

Attorney Docket Number

TAKAYAMA=10

				FC	DREIG	N PATENT DOCUMEN	TS		
		Foreign Patent Number							
Examiner Initials*		Office <sup>3</sup>	Number		Code⁵ nown)	Applicant/Inventor of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	1 <sub>0</sub>
1	AG-	JP	0 41059			MIYAMOTO et al.	Feb. 15, 1994		XXX
	AH	JP	10 182597			TAKAHASHI et al.	July 7, 1998		xxx
20.	A.A.	JP	06 256300			TAKANO et al.	Sept. 13, 1994		xxx
552	AJ	PCT	94 14766			GRUE-SØRENSEN	July 7, 1994		
	AK	PCT	96 01811			POSNER	Jan. 25, 1996		
	,- <sub></sub> ,	A	H+AI	Eng	list	h abstract	Provi	sed,	
		*	no ab	810	ael	<i>L</i> -,			

Examiner Signature	Sabiha Ooza	Date Considered	4/5/03	
-----------------------	-------------	--------------------	--------	--

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2		of	2	
Officer	-		0.	_	

Complete if Known					
Application Number	10/069,481				
Filing Date	February 27, 2002				
First Named Inventor	H. TAKAYAMA et al.				
Group Art Unit	100				
Examiner Name					
Attorney Docket Number	TAKAYAMA=10				

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AL	KONNO et al., "A novel and practical Route to A-Ring Enyne Synthon for 1α, 25-Dihydroxyvitamin D₃ Analogs: Synthesis of A-Ring Diasteromers of 1α, 25-Dihydroxy-vitamin D₃ and 2-Methyl-1, 25-Dihydroxyvitamin D₃, Bioorganic & Medical Chemistry Letters, (1998), vol. 8, pages 151-156	
50%	AM	FIJISHIMA et al., "Synthesis and Biological Activity of-Methyl-20-EPI Analogues of 1α, 25-Dihydroxyvitamin D <sub>3</sub> , "Bioorganic & Medical Chemistry Letters, (1998), vol. 8, Pages 2145-2148	
	AN	ONO et al., "Synthetic Studies of Vitamin D Analogs. XXVI. <sup>1)</sup> Synthesis of Active Vitamin D <sub>3</sub> Analogs Substituted at the 2β-Position and Teir Preventive Effects of Bone Mineral Loss in Overiectomized Rats <sup>2)</sup> , Chem. Pharm. Bull., (1997), vol. 45, No. 10, pages 1626-1630	
	AO	SUHARA et al., "Synthesis and Biological Evaluation ofNovel 2α-Substituted 1α, 25-Dihydroxyvitamin D <sub>3</sub> Analogues", <u>Bioorganic &amp; Medical Chemistry Letters,</u> (2000), vol. 10, pages 1129-1132	

Examiner Signature	Sabiha	Ozz	Date Considered	4/5/03
				7

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/069,481

Filing Date February 27, 2002

First Named Inventor H. Takayama et al.

Group Art Unit 1616

Examiner Name

Attorney Docket Number

TAKAYAMA=10

Sheet

of

				U.S. PATENT DOCUM	IENTS	
Examiner nitials*	Cite No.1	U.S. Patent I Number	Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant/Inventor	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	7					
	\					
ĺ			E.			
Ì						
					/	

				FOREIG	IN PATENT DOCUMEN	TS			
			Foreign Patent Num		Name of Patentee or	Date of Publication			
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number	Kind Code⁵ (if known)	Applicant/Inventor of Cited Document	Applicant/Inventor of Cited   of Cited Document   Where Relevant Fig.   MM-DD-YYYY   Relevant Fig.		nt Passages or jures Appear T <sup>6</sup>	
	AA	wo	00 66548		SHAMOTO et al.	Nov. 9, 2000		xxx	
			FI		led				
		-2	ich pr	one					
			/						
ļ									
							•		

Examiner	Signific	B121	Date	4/5/2003
Signature	a HIST HT	CAPZI	Considered	1/5/20

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO 10/069,481 **Application Number** INFORMATION DISCLOSURE February 27, 2002 Filing Date STATEMENT BY APPLICANT H. Takayama et al. **First Named Inventor** 1616 Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet of Attorney Docket Number TAKAYAMA=10

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
C.B.	АВ	POSNER et al., "Stereocontrolled Total Synthesis of Calcitriol Derivatives: 1, 25-Dihydroxy-2-(4'-hydroxybutyl) vitamin D₃ Analogs of an Osteoporosis Drug", <u>J. Org. Chem.</u> , vol. 59, No. 25, Pages 7855-7861	
	·		
·			
Examine Signatur		SABIHA SAZI Date Considered 4/5/2003	$\overline{1}$

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.